BidaskClub Upgrades Glaukos Corporation (GKOS) to Hold
Glaukos Corporation (NYSE:GKOS) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
Several other equities analysts have also weighed in on GKOS. Zacks Investment Research lowered Glaukos Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $54.00 target price on shares of Glaukos Corporation in a research note on Thursday, May 4th. TheStreet lowered Glaukos Corporation from a “c” rating to a “d+” rating in a research note on Wednesday, May 3rd. Stephens raised Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a research note on Monday, May 8th. Finally, Roth Capital dropped their price target on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $52.33.
Glaukos Corporation (NYSE GKOS) traded down 0.42% during mid-day trading on Wednesday, reaching $37.81. The company’s stock had a trading volume of 352,149 shares. Glaukos Corporation has a 12 month low of $28.26 and a 12 month high of $52.49. The stock’s 50 day moving average is $39.90 and its 200 day moving average is $43.22. The company’s market cap is $1.30 billion.
Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in Glaukos Corporation during the fourth quarter worth approximately $513,000. Teachers Advisors LLC raised its stake in Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock worth $953,000 after buying an additional 1,506 shares in the last quarter. Bank of Montreal Can acquired a new stake in Glaukos Corporation during the first quarter worth approximately $3,196,000. Navellier & Associates Inc raised its stake in Glaukos Corporation by 25.1% in the first quarter. Navellier & Associates Inc now owns 31,740 shares of the medical instruments supplier’s stock worth $1,628,000 after buying an additional 6,374 shares in the last quarter. Finally, Nationwide Fund Advisors raised its stake in Glaukos Corporation by 749.3% in the first quarter. Nationwide Fund Advisors now owns 89,101 shares of the medical instruments supplier’s stock worth $4,571,000 after buying an additional 78,610 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.